Pneumological Line

AEROPLÚS

Anti-asthmatic. Non-halogenated corticosteroid.

Pressurized metered dose inhaler.

Formula:

Each valve activation supplies 200 mcg of Budesonide, Excipient q.s.

It contains propellant that does not affect the ozone layer.

Indications:

Asthma treatment, medication for prevention and maintenance, not for rescue.

Dosage:

Minimal doses are recommended which keep the patient asymptomatic.

Children 6 to 12 years old: 1 to 2 inhalations of 200 mcg 1-2 times a day. Maximum dose 800 mcg (4 inhalations).

Adults: 1 to 4 inhalations of 200 mcg 1 to 2 times a day. Maximum dose 1600 mcg (8 inhalations).

Instruct on the proper use of the inhaler.

Children and the elderly are advised to use inhalochamber.

Presentation:

Package of 200 doses.

Route of administration:

Oral inhale.

ESTRAPLÚS

Short action beta 2 agonist adrenergic bronchodilator, associated to an anticholinergic bronchodilator.

Pressurized metered dose inhaler.

Formula:

Each valve activation supplies 20 mcg of Ipratropium Bromide and 100 mcg of Salbutamol (as Sulphate).

It contains propellant that does not affect the ozone layer.

Indications:

Chronic Obstructive Pulmonary Disease (COPD). For the prevention and treatment of chronic disorders of the respiratory track with reversible bronchospasm, including chronic bronchitis, with or without emphysema.

Dosage:

Children: Safety and efficacy have not been established.

Adults: one or two doses 3 or 4 times per day with an interval of 4 hours between them. Inhalations can be performed as required. Do not exceed 12 inhalations in 24 hours.

Instruct on the proper use of the inhaler.

Children and the elderly are advised to use inhalochamber.

Presentation:

Package of 200 doses.

Route of administration:

Oral inhale.

ESTRAVENT

Anticholinergic bronchodilator. Acts on the parasympathetic receptors inhibiting the formation (via cyclic GMP) of bronchospasm mediators.

Pressurized metered dose inhaler.

Formula:

Each valve activation supplies 20 mcg of Ipratropium Bromide, excipients q.s.

It contains propellant that does not affect the ozone layer.

Indications:

Maintenance treatment of bronchospasm associated with Chronic Obstructive Pulmonary Disease (COPD) including chronic bronchitis and emphysema.

Dosage:

Usual starting dose of 2 inhalations 4 times a day. If required, the patient may use additional inhalations, not exceeding 12 inhalations in 24 hours.

Instruct on the proper use of the inhaler.

Children and the elderly are advised to use inhalochamber.

Presentation:

200 dose packages.

Route of administration:

Oral inhale.

INHALPLÚS

Potent corticosteroid.

Pressurized metered dose inhaler.

Formula:

Inhalplus 50: each valve activation supplies 50 mcg of Fluticasone Propionate, excipients q.s.

Inhalplus 125: each valve activation supplies 125 mcg of Fluticasone Propionate, excipients q.s.

Inhalplus 250: each valve activation provides 250 mcg of Fluticasone Propionate, excipients q.s.

It contains propellant that does not affect the ozone layer.

Indications:

Maintenance treatment of asthma as preventive therapy as well as for those patients requiring asthma treatment with oral corticosteroids that by using inhaled fluticasone can reduce or eliminate the orally administered corticosteroid in a progressive way. It is not a rescue medication.

It reduces symptoms and exacerbations in patients previously treated with bronchodilators exclusively or with other preventive therapy. Inhalplús is indicated for the maintenance treatment of Chronic Obstructive Pulmonary Disease. Its use causes benefits to lung function and reduces symptoms.

Dosage:

Mild asthma: Children over 4 years: 100 to 200 mcg/day dose repeated every 12 hours. Over 16 years 200 to 500 mcg/day dose repeated every 12 hours.

Moderate asthma: Children over 4 years: from 100 to 200 mcg/day dose repeated every 12 hours. Over 16 years 500-1000 mcg/day dose repeated every 12 hours.

Severe asthma: Children over 4 years: from 100 to 200 mcg/day dose repeated every 12 hours. Over 16 years from 1000 to 2000 mcg/day dose repeated every 12 hours.

Patients with Chronic Obstructive Pulmonary Disease: Children under 1 to 4 years 100 mcg dose twice a day with mask and inhalochamber.

Adult dose: 500 mcg twice a day, everyday use, the benefit is observed after 3 to 6 months of treatment. This dosage is amended according to the therapeutic response of the patient.

It is a medication of regular use, prophylactically.

The patient should be informed that the use of the medication must be continued even if asymptomatic.

Instruct on the proper use of the inhaler.

Its therapeutic effect will be seen 4 to 7 days after starting treatment, although improvements can be observed 24 hours after the patient receives the medication, in patients who have not received prior therapy with inhaled corticosteroids.

Once stability is achieved it is important to register the lowest effective dose in order to reduce side effects and maintain the asthma controlled.

No dose adjustment is necessary in geriatric patients with kidney or liver failure.

Children and the elderly are advised to use inhalochamber.

Presentation:

Inhalplus 50 - packages of 60 - 120 doses.

Inhalplus 125 – packages of 60 - 120 doses.

Inhalplus 250 - packages of 60 - 120 doses.

Route of administration:

Oral inhale.

MONTELAIR

Anti-asthmatic and antiallergic. It blocks the activity of the leukotrienes at the level of the respiratory track. Reduces bronchial hyperreactivity, bronchoconstriction and mucus hypersecretion.

Formula:

Montelair 10 mg: Each tablet contains Montelukast (as sodium) 10 mg.

Montelair 5 mg: Each chewable tablet contains Montelukast (as sodium) 5 mg.

Indications:

For prophylaxis and chronic treatment of asthma in adults and children over 2 years, including the prevention of day and night symptoms. For prevention of exercise-induced asthma in people over 6 years. For seasonal allergic rhinitis in children over 2 years.

Dosage:

For patients 2 to 5 years old 4 mg a day. Pediatric patients from 6 to 14 years 1 chewable tablet of Montelukast 5 mg, once a day, preferably before bedtime.

Adults and teenagers aged 15 years and over a coated tablet of 10 mg of Montelukast preferably before bedtime.

For prevention of exercise-induced asthma, a single dose administered 2 hours before exercise. Additional doses should not be taken within 24 hours of the previous dose. Patients who are taking this product daily should not take extra doses for exercise-induced asthma. Patients must have a rescue medication, a beta 2 agonist of short duration.

Presentation:

Montelair 10 mg: Packs of 10 and 30 coated tablets.

Montelair 5 mg: Packs of 10 and 30 chewable tablets.

Route of administration:

Oral.

OXIPLÚS

Corticosteroid.

Pressurized metered dose inhaler.

Formula:

Each valve activation supplies 50 mcg of Beclomethasone Dipropionate.

It contains propellant which does not affect the ozone layer.

Indications:

Maintenance treatment of asthma as prophylactic therapy in patients over 5 years old.

For patients with asthma who require systemic corticosteroid administration and the administration of Beclomethasone Dipropionate may reduce or eliminate the need for systemic corticosteroids.

Dosage:

Children 6 to 12 years: 1 or 2 inhalations of 50 mcg, 2 to 4 times a day (maximum dose 400 mcg/day).

Adults and children over 12 years: from 200 to 1000 mcg/day, in 2 to 4 doses.

Instruct on the proper use of the inhaler.

Children and the elderly are advised to use inhalochamber.

Presentation:

Package of 200 doses.

Route of administration:

Oral inhale.

OXIPLÚS 5F

Corticosteroid.

Pressurized metered dose inhaler.

Formula:

Each valve activation supplies 250 mcg of Beclomethasone Dipropionate.

It contains propellant which does not affect the ozone layer.

Indications:

Maintenance treatment of asthma as a prophylactic therapy in patients over 5 years old.

For asthma patients who require systemic corticosteroid administration and the administration of Beclomethasone Dipropionate may reduce or eliminate the need for systemic corticosteroids.

Dosage:

Children 6 to 12 years: 1 or 2 inhalations of 50 mcg, two to four times a day (maximum dose 400 mcg/day).

Adults and children over 12 years: from 200 to 1000 mcg/day, in two to four doses.

Instruct on the proper use of the inhaler.

Children and the elderly are advised to use inhalochamber.

Presentation:

Package of 200 doses.

Route of administration:

Oral inhale.

SERFLÚ

Lond acting (12 hours) beta 2 agonist adrenergic bronchodilator, associated with corticosteroid.

Pressurized metered dose inhaler.

Formula:

Serflú 50: each valve activation supplies 25 mcg of Salmeterol (as xinafoate) and 50mcg of Fluticasone Propionate, excipients q.s.

Serflú 125: each valve activation supplies 25 mcg of Salmeterol (as xinafoate) and 125 mcg of Fluticasone Propionate, excipients q.s.

Serflú 250: each valve activation supplies 25 mcg of Salmeterol (as xinafoate) and 250 mcg of Fluticasone Propionate, excipients q.s.

It contains propellant that does not affect the ozone layer.

Indications:

Treatment of reversible obstructive diseases of the respiratory track, asthma. It will only be prescribed in patients not adequately controlled with an asthma medication that controls it long-term, as an inhaled corticosteroid or when the severity of the disease requires the initiation of treatment with an inhaled corticosteroid and a long-acting beta agonist. Patients with effective low doses of maintenance, with long-acting beta agonists and inhaled corticosteroids. Patients with bronchodilators requiring inhaled corticosteroids. Symptomatic patients being treated with inhaled corticosteroids. Once the control and maintenance of asthma is achieved, the patient should be preferably maintained with an inhaled corticosteroid.

Serflú is not a rescue medication.

It is indicated for the regular treatment of Chronic Obstructive Pulmonary Disease including chronic bronchitis and emphysema.

Dosage:

Children over 4 years old: 2 inhalations of Serflú 50 twice a day.

Adults and adolescents over 12 years old: 2 inhalations of Serflú 50 twice a day or 2 inhalations of Serflú 125 twice a day or 2 inhalations of Serflú 250 twice a day.

Patients with Chronic Obstructive Pulmonary Disease: Adults, the dose may vary from 2 inhalations of Serflú 125 twice a day to 2 inhalations of Serflú 250 twice a day.

Serflú must be used regularly in order to get the best benefits. Even with the asymptomatic patient.

It requires periodical medical control in order to adjust doses.

In case of asthma and reversible obstructive respiratory track disease it is convenient to inhale the lowest dose possible to achieve good control of symptoms. The maximum recommended dose is 2 inhalations twice a day.

If the control of symptoms with Serflú twice a day is achieved, it is possible to make an adjustment to a lower effective dose requiring the administration of Serfllú only once a day. The recommended starting dose will be in relation to the severity of the patient's asthma.

Instruct on the proper use of the inhaler.

Children and the elderly are advised to use inhalochamber.

Presentation:

Serflú 50 – packages of 60 - 120 doses.

Serflú 125 – packages of 60 - 120 doses.

Serflú 250 – packages of 60 - 120 doses.

Route of administration:

Oral inhale.

VENTIPLÚS

Short action beta 2 agonist adrenergic bronchodilator. Rescue medication.

Pressurized metered dose inhaler.

Formula:

Each valve activation supplies 100 mcg of Salbutamol (as sulphate), excipients q.s.

It contains propellant that does not affect the ozone layer.

Indications:

Bronchodilator of short duration and fast onset of action. For the treatment or prevention of bronchospasm in patients over 4 years old with reversible obstructive pulmonary disease, asthma and patients with chronic bronchitis and emphysema. Indicated in exercise-induced asthma in patients over 4 years old. Ventiplús inhaler is a rescue medication indicated for asthma attacks, both for controlled, partially controlled or uncontrolled asthma (GINA guidelines).

Dosage:

For the treatment of acute episodes of bronchospasm, the recommended dose is two repeated inhalations every 4 to 6 hours for children over 4 years old and adults. It is not advisable to increase the frequency or the number of inhalations. Minors: 100 mcg which may increase to 200 mcg. Adults: 100 to 200 mcg.

For exercise-induced asthma the recommended dose for children aged 4 and older and adults is of 2 inhalations, 15 to 30 minutes before exercise. Minors: 100 mcg (1 dose) which may increase to 200 mcg (2 doses). Adults: 100 to 200 mcg (1 or 2 doses). This dosage is amended according to the therapeutic response of the patient.

Ventiplús is characterized by its quick action (approximately 5 minutes) and short duration (between 4 and 6 hours).

The patient should be educated in asthma and informed that the increased use of Beta 2 agonists (Ventiplús) may indicate a loss of control on asthma, so you should consult your doctor.

Instruct on the proper use of the inhaler.

Children and the elderly are advised to use inhalochamber.

Presentation:

Packages of 250 doses.

Route of administration:

Oral inhale.

VENTOXIPLÚS

Short action beta 2 agonist adrenergic bronchodilator, associated to corticosteroid.

Pressurized metered dose inhaler.

Formula:

Each valve activation supplies 100 mcg of Salbutamol (as Sulphate) plus 50 mcg of Beclomethasone Dipropionate, excipients q.s.

It contains propellant that does not affect the ozone layer.

Indications:

It contains an inhaled corticosteroid with anti-inflammatory action, Beclomethasone Dipropionate associated with a beta 2 agonist bronchodilator of short duration Salbutamol.

Indicated for maintenance treatment of asthma, chronic bronchitis, emphysema, so in patients who require regular doses of both medications for the treatment of obstructive respiratory track disease.

Dosage:

Ventoxiplús must be used regularly. The patient should be periodically reexamined in order to review the continued need for corticosteroid therapy.

Children: 1 to 2 inhalations 2, 3 to 4 times a day.

Adults: 1 or 2 inhalations, 3 to 4 times daily.

This dosage is amended according to the therapeutic response of the patient.

Instruct on the proper use of the inhaler.

Children and the elderly are advised to use inhalochamber.

Presentation:

200 dose package.

Route of administration:

Oral inhale.